Evaluation of Natural Human Interferon Alpha Lozenges in the Treatment of Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF).

Trial Profile

Evaluation of Natural Human Interferon Alpha Lozenges in the Treatment of Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2012

At a glance

  • Drugs Interferon alpha (Primary)
  • Indications Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 23 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Apr 2012 Actual patient number is 1 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top